高级检索

康柏西普联合阿托伐他汀治疗高血脂合并糖尿病性黄斑水肿的疗效观察

李彬彬, 胡莉群, 谭美华, 赖飞民

李彬彬, 胡莉群, 谭美华, 赖飞民. 康柏西普联合阿托伐他汀治疗高血脂合并糖尿病性黄斑水肿的疗效观察[J]. 实用临床医药杂志, 2020, 24(22): 41-43. DOI: 10.7619/jcmp.202022011
引用本文: 李彬彬, 胡莉群, 谭美华, 赖飞民. 康柏西普联合阿托伐他汀治疗高血脂合并糖尿病性黄斑水肿的疗效观察[J]. 实用临床医药杂志, 2020, 24(22): 41-43. DOI: 10.7619/jcmp.202022011
shu
LI Binbin, HU Liqun, TAN Meihua, LAI Feimin. Effect observation of conbercept combined with atorvastatin in the treatment of hyperlipidemia complicated with diabetic macular edema[J]. Journal of Clinical Medicine in Practice, 2020, 24(22): 41-43. DOI: 10.7619/jcmp.202022011
Citation: LI Binbin, HU Liqun, TAN Meihua, LAI Feimin. Effect observation of conbercept combined with atorvastatin in the treatment of hyperlipidemia complicated with diabetic macular edema[J]. Journal of Clinical Medicine in Practice, 2020, 24(22): 41-43. DOI: 10.7619/jcmp.202022011
shu

康柏西普联合阿托伐他汀治疗高血脂合并糖尿病性黄斑水肿的疗效观察

  • 江西省赣州市人民医院 眼科, 江西 赣州, 341000

基金项目: 

江西省卫生计生委科技计划项目(20187237)

详细信息

  • 中图分类号: R972;R58

Effect observation of conbercept combined with atorvastatin in the treatment of hyperlipidemia complicated with diabetic macular edema

  • Department of Ophthalmology, Ganzhou City People's Hospital in Jiangxi Province, Ganzhou, Jiangxi, 341000

摘要

    摘要
  • 摘要: 目的 观察康柏西普联合阿托伐他汀治疗高血脂合并糖尿病性黄斑水肿的临床疗效。 方法 选取94例2型糖尿病合并高血脂、非增殖性糖尿病视网膜病变、黄斑水肿及黄斑硬性渗出的患者,随机分为观察组和对照组,每组47例。对照组采用视网膜激光光凝治疗,观察组采用玻璃体腔注射康柏西普联合口服阿托伐他汀钙片治疗。比较2组患者治疗前和治疗6个月后的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平,分析黄斑水肿、渗出及视力变化。 结果 治疗后, 2组TC、TG、LDL-C水平较治疗前下降, HDL-C水平较治疗前升高,且观察组TC、TG、LDL-C水平低于对照组, HDL-C水平高于对照组,差异均有统计学意义(P<0.05)。治疗后, 2组黄斑水肿、黄斑区硬性渗出及最佳矫正视力均较治疗前好转,且观察组优于对照组,差异均有统计学意义(P<0.05)。 结论 玻璃体腔注射康柏西普联合口服阿托伐他汀钙片能有效改善血脂代谢情况,减轻黄斑水肿和黄斑区硬性渗出,进而改善视力。
    Abstract: Objective To observe the clinical effect of conbercept combined with atorvastatin in the treatment of hyperlipidemia complicated with diabetic macular edema. Methods Totally 94 type 2 diabetes patients complicated with hyperlipidemia, non-proliferative diabetic retinopathy, macular edema, and macular hard exudation were selected and randomly divided into observation group and control group, with 47 cases in each group. The control group was treated with laser photocoagulation, while the observation group was treated with intravitreal injection of conbercept combined with oral taken atorvastatin calcium tablets. The levels of total cholesterol(TC), triglycerides(TG), high-density lipoprotein cholesterol(HDL-C)and low-density lipoprotein cholesterol(LDL-C)before treatment and 6 months after treatment were compared between two groups, and changes in macular edema, exudation and visual acuity were analyzed. Results After treatment, the levels of TC, TG and LDL-C in both groups were significantly lower than those before treatment, while the HDL-C level was significantly higher than that before treatment, and the levels of TC, TG and LDL-C in the observation group were significantly lower than those in the control group, and the HDL-C level was significantly higher than that in the control group(P<0.05). After treatment, macular edema, macular hard exudation and best corrected visual acuity were improved in both groups, and these indexes in the observation group were significantly better than the control group(P<0.05). Conclusion Intravitreal injection of conbercept combined with oral taken atorvastatin calcium tablets can effectively improve blood lipid metabolism, reduce degrees of macular edema and macular hard exudation, and - improve visual acuity.
    • HTML全文
    • 参考文献(12)

  • KAHNERT K, LUCKE T, HUBER R M, et al. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort[J]. PLoS One, 2017, 12(5): e0177501.

    MATOGA M M, HOSSEINIPOUR M C, AGA E, et al. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings[J]. Antivir Ther, 2017, 22(3): 205-213.
    丁国鹏, 丁国龙, 雷姝, 等. 康柏西普联合577nm微脉冲激光治疗糖尿病性黄斑水肿临床观察[J]. 国际眼科杂志, 2015, 15(11): 1942-1944.

    THEODOSIS-NOBELOS P, PAPAGIOUVANNIS G, KOUROUNAKIS P N, et al. Active anti-inflammatory and hypolipidemic derivatives of lorazepam[J]. Molecules, 2019, 24(18): E3277-E3283.
    孙清磊, 罗媛媛, 宋颖, 等. 糖尿病性黄斑水肿的发病机制与治疗进展[J]. 中华老年多器官疾病杂志, 2015, 14(1): 33-38.
    郭永兰, 赵亮亮, 聂黎黎, 等. 糖尿病性黄斑水肿的发病机制及治疗进展[J]. 国际老年医学杂志, 2019, 40(2): 116-119.
    唐孟苏, 张淑琦, 马立威. 曲安奈德球周注射联合阈下值微脉冲激光对糖尿病性黄斑水肿的疗效观察[J]. 中国实用眼科杂志, 2018, 36(5): 364-367.
    姜林, 杨红, 张世慧. 曲安奈德玻璃体腔注射联合视网膜激光光凝术在糖尿病黄斑水肿患者中的临床应用及安全性评价[J]. 实用临床医药杂志, 2017, 21(5): 167-169.
    李文清, 宋艳萍, 丁琴. 康柏西普联合577 nm阈值下微脉冲激光光凝治疗糖尿病黄斑水肿的疗效观察[J]. 中华眼底病杂志, 2019, 35(2): 129-134.

    DEMIR V, DO?RU M T, EDE H, et al. The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia[J]. Cardiovasc J Afr, 2018, 29(3): 162-166.
    王海山, 张海军, 李玉军, 等. 雷珠单抗玻璃体腔注射并激光光凝治疗糖尿病性黄斑水肿疗效观察[J]. 中国实用眼科杂志, 2015, 33(1): 25-29.
    张召弟, 郭晟, 李娟, 等. 康柏西普和雷珠单抗治疗弥漫性糖尿病性黄斑水肿的疗效比较[J]. 广西医学, 2018, 40(5): 500-502

    , 517.
    • 相关文章
    • 施引文献(10)

  • 期刊类型引用(10)

    1. 吴启红，郭良晨，丁圣星，王丹. 阿托伐他汀钙片治疗老年白内障术后患者的效果. 中外医学研究. 2024(17): 25-28 . 百度学术
    2. 江丽华，席巍，蔡鑫. 增殖型2型糖尿病视网膜病变患者外周血ADAMTS13表达及对阿托伐他汀干预效果的评估价值. 河北医科大学学报. 2024(09): 1053-1057 . 百度学术
    3. 杨凯转，乔玉好，闫淑. 玻璃体内注射抗VEGF药物对糖尿病黄斑水肿患者疗效的影响因素分析. 眼科新进展. 2023(04): 298-302+307 . 百度学术
    4. 郭宓，边红霞，边梦婷，刘瑞英，李志光，马果敏，姚炎焱. 康柏西普治疗不同OCT分型糖尿病性黄斑水肿对视网膜椭圆体带影响. 临床眼科杂志. 2023(02): 121-125 . 百度学术
    5. 黄波. 玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿的临床疗效分析. 中国现代药物应用. 2022(03): 187-189 . 百度学术
    6. 王淑娜，高武勤，邓海波. 抗血管内皮生长因子药物治疗糖尿病黄斑水肿患者的预后因素分析. 中国当代医药. 2022(09): 80-82 . 百度学术
    7. 王子传，张小妹，李财保. 康柏西普联合激光光凝治疗糖尿病性黄斑水肿的效果. 中国当代医药. 2022(09): 83-86 . 百度学术
    8. 巨朝娟，张骞颖，邢朋欣，石笑楠，张新. 抗血管内皮细胞生长因子治疗糖尿病性黄斑水肿的疗效及光学相干断层扫描血管造影结果分析. 中国现代医学杂志. 2022(10): 36-41 . 百度学术
    9. 王敏玲，沈丹青，李美秀. 生蒲黄汤加减辅治糖尿病变伴黄斑水肿临床研究. 实用中医药杂志. 2021(11): 1856-1858 . 百度学术
    10. 于倩. 血脂康胶囊联合阿托伐他汀治疗高脂血症的应用效果分析. 中西医结合心血管病电子杂志. 2021(33): 64-66 . 百度学术

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  398
  • HTML全文浏览量:  60
  • PDF下载量:  18
  • 被引次数: 10
出版历程
  • 收稿日期:  2020-09-14
  • 网络出版日期:  2020-12-21
  • 发布日期:  2020-12-02

目录

摘要
HTML全文
    参考文献(12)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭